Logo image
Antiplatelet therapy and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis
Journal article   Peer reviewed

Antiplatelet therapy and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis

M. Harrison Snyder, Natasha Ironside, Jeyan S. Kumar, Kevin T. Doan, Ryan T. Kellogg, J. Javier Provencio, Robert M. Starke, Min S. Park, Dale Ding and Ching-Jen Chen
Journal of Neurosurgery, Vol.137(1)
2022

Abstract

acetylsalicylic acid antithrombocytic agent cilostazol clopidogrel ozagrel adult aged aneurysm surgery anticoagulant therapy black checklist bleeding brain angiography brain artery aneurysm rupture brain ischemia brain vasospasm cerebral revascularization clinical outcome cohort analysis comparative study controlled study delayed cerebral ischemia downs checklist drug efficacy drug safety dual antiplatelet therapy endovascular aneurysm repair female functional status human in-hospital mortality male Medline meta analysis middle aged monotherapy outcome assessment publication bias quality assessment tool quality control randomized controlled trial (topic) retrospective study Review subarachnoid hemorrhage systematic review
OBJECTIVE Delayed cerebral ischemia (DCI) is a potentially preventable cause of morbidity and mortality after aneurysmal subarachnoid hemorrhage (aSAH). The authors performed a meta-analysis to assess the effect of antiplatelet therapy (APT) on DCI in patients with aSAH. METHODS A systematic review of the PubMed and MEDLINE databases was performed. Study inclusion criteria were 1) ≥ 5 aSAH patients; 2) direct comparison between aSAH management with APT and without APT; and 3) reporting of DCI, angiographic, or symptomatic vasospasm rates for patients treated with versus without APT. The primary efficacy outcome was DCI. The outcomes of the APT versus no-APT cohorts were compared. Bias was assessed using the Downs and Black checklist. RESULTS The overall cohort comprised 2039 patients from 15 studies. DCI occurred less commonly in the APT compared with the no-APT cohort (pooled = 15.9% vs 28.6%; OR 0.47, p < 0.01). Angiographic (pooled = 51.6% vs 68.7%; OR 0.46, p < 0.01) and symptomatic (pooled = 23.6% vs 37.7%; OR 0.51, p = 0.01) vasospasm rates were lower in the APT cohort. In-hospital mortality (pooled = 1.7% vs 4.1%; OR 0.53, p = 0.01) and functional dependence (pooled = 21.0% vs 35.7%; OR 0.53, p < 0.01) rates were also lower in the APT cohort. Bleeding event rates were comparable between the two cohorts. Subgroup analysis of cilostazol monotherapy compared with no APT demonstrated a lower DCI rate in the cilostazol cohort (pooled = 10.6% vs 28.1%; OR 0.31, p < 0.01). Subgroup analysis of surgically treated aneurysms demonstrated a lower DCI rate for the APT cohort (pooled = 18.4% vs 33.9%; OR 0.43, p = 0.02). CONCLUSIONS APT is associated with improved outcomes in aSAH without an increased risk of bleeding events, particularly in patients who underwent surgical aneurysm repair and those treated with cilostazol. Although study heterogeneity is the most significant limitation of the analysis, the findings suggest that APT is worth exploring in patients with aSAH, particularly in a randomized controlled trial setting. © AANS 2022.

Details

Logo image